News on proteomics applications for clinical use in genetics, genomics, and molecular diagnostics.
The firms will initially use RenalytixAI's KidneyIntelX platform to help improve outcomes for patients with chronic kidney disease and its complications.
BostonGene will analyze the tumors of patients enrolled in NEC or NEC-affiliated clinical trials and NEC will use the data to help improve treatment responses.
A survey asking researchers for their thoughts on the key developments in the field turned up applications ranging from clinical to structural.
The researchers used the SomaScan platform to measure 5,000 plasma proteins across 17,000 patients and develop protein profiles correlated to 11 health conditions.
The company will test a peptide array approach that it believes can identify MSI-high, immunotherapy-responsive individuals more cheaply and easily than existing tests.
